56 results on '"Yāng Z"'
Search Results
2. Myelopreservation with the CDK4/6 inhibitor trilaciclib in patients with small-cell lung cancer receiving first-line chemotherapy: a phase Ib/randomized phase II trial
3. 1730P Preliminary results of phase II study on preoperative intensity-modulated radiotherapy with concurrent PARP inhibitor for patients with non-metastatic inoperable or borderline operable extremity and trunk soft tissue sarcoma
4. 1610P Circulating tumour cell (CTC) enumeration and overall survival (OS) in men with metastatic castration-resistant prostate cancer (mCRPC) treated with xaluritamig
5. 1598P Xaluritamig, a STEAP1 x CD3 XmAb 2+1 immune therapy, in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC): Initial results from dose expansion cohorts in a phase I study
6. 1441P Clinical application of a machine learning-based pathomics signature for predicting lymph node metastasis in early gastric cancer
7. 888P Comparing paclitaxel plus cisplatin versus cisplatin in concurrent chemoradiotherapy for stage IV locoregionally advanced nasopharyngeal carcinoma: A phase II randomized trial
8. 728P Chemotherapy plus tislelizumab in young patients with cervical cancer preserve fertility: A phase II study
9. 680TiP A phase I/IIa first-in-human clinical trial evaluating MDX2001, a multi-specific antibody in patients with advanced solid tumor malignancies
10. 526P Efficacy and safety of fruquintinib in refractory metastatic colorectal cancer: A FRESCO-2 subgroup analysis by age
11. 453MO A phase I study for safety, tolerability, pharmacokinetics, and anti-tumor activity of ABM-1310 in patients (pts) with BRAF V600 mutated recurrent primary brain tumours: Interim result
12. Validation of the simplified Chinese version of EORTC QLQ-C30 from the measurements of five types of inpatients with cancer
13. 264P Interim results from a phase I study of AMG 509 (xaluritamig), a STEAP1 x CD3 XmAb 2+1 immune therapy in patients with metastatic castration-resistant prostate cancer (mCRPC)
14. LBA33 A first-in-human phase I study of a novel KRAS G12D inhibitor HRS-4642 in patients with advanced solid tumors harboring KRAS G12D mutation
15. 1765O Interim results from a phase I study of AMG 509 (xaluritamig), a STEAP1 x CD3 XmAb 2+1 immune therapy, in patients with metastatic castration-resistant prostate cancer (mCRPC)
16. 1069P Potential biomarkers for predicting severe immune-related adverse events during checkpoint immunotherapy: T Cell receptor and whole exome sequencing findings from a prospective multicenter study
17. 743MO Efficacy and safety of QL1706 plus paclitaxel and cisplatin/carboplatin +/- bevacizumab (Bev) as 1L treatment in recurrent or metastatic cervical cancer (r/mCC): A single-arm, multicenter phase II study
18. 642P A phase I dose escalation study of GCC19CART: A novel CoupledCAR therapy for subjects with metastatic colorectal cancer
19. 388P Capmatinib in Chinese adults with EGFR wt, ALK rearrangement negative (ALK-R−), MET exon 14 skipping mutation (METex14), advanced NSCLC: Results from the phase II GEOMETRY-C study
20. 47P Safety and efficacy evaluation of long-course neoadjuvant chemoradiotherapy plus tislelizumab followed by total mesorectal excision for locally advanced rectal cancer: Intermediate results of a multicenter, phase II study
21. 46MO FRESCO-2: A global / multiregional phase III clinical trial (MRCT) evaluating the efficacy and safety of fruquintinib in patients with metastatic colorectal cancer
22. LBA25 FRESCO-2: A global phase III multiregional clinical trial (MRCT) evaluating the efficacy and safety of fruquintinib in patients with refractory metastatic colorectal cancer
23. 1177P Clinical implications of TSC1/TSC2 variants on immunotherapy in NSCLC patients
24. P-248 Identification of serpin peptidase inhibitor clade A member 1 as a novel serum biomarker for gastric cancer and promotion of liver metastasis
25. P-167 Identification of peptides inhibitor clade A member 1 as a novel serum biomarker for gastric cancer and promotes liver metastasis
26. 4MO Final overall survival (OS) data of sintilimab plus pemetrexed (SPP) and platinum as first-line (1L) treatment for locally advanced or metastatic nonsquamous NSCLC (AMnsqNSCLC) in the phase III ORIENT-11 study
27. 8MO The efficacy and safety of TQ-B3101 monotherapy in the first-line treatment in patients with ROS1-positive non-small cell lung cancer
28. 3MO First-line camrelizumab plus carboplatin and paclitaxel for advanced squamous non-small cell lung cancer: Updated overall survival results from the phase III CameL-sq trial
29. 150P Subgroup analysis of ORIENT12: Efficacy of sintilimab in combination with gemcitabine and platinum-based chemotherapy in patients with advanced or metastatic squamous non-small cell lung cancer
30. 94P Patient-reported outcomes (PROs) following sintilimab (sint) plus pemetrexed (pem) and platinum (plt) based chemotherapy as first-line therapy for locally advanced or metastatic nonsquamous NSCLC: A randomized, double-blind, phase III study (Orient-11)
31. 1225P The progression-free survival of the first-line EGFR-TKI is a strong prognosticator of the second-line osimertinib in non-small cell lung cancer (NSCLC) patients with EGFR-T790M mutation: A real-world study
32. 1163P Combined large cell neuroendocrine carcinoma: Clinical characteristics, prognosis and postoperative management
33. 913P Apatinib for heavily pretreated recurrent and/or metastatic head and neck squamous cell carcinoma: Updated analysis
34. 337TiP An open-label, phase Ib/II study to evaluate the safety and efficacy of fruquintinib in combination with tislelizumab in patients with advanced triple-negative breast cancer
35. 155P The addition of pyrotinib in early or locally advanced HER2-positive breast cancer patients with no response to two cycles of neoadjuvant therapy: A prospective, multicenter study
36. 2P Molecular imaging evaluation of a novel Claudin18.2 specific monoclonal antibody labeled with radionuclide
37. LBA56 ORIENT-12: Sintilimab plus gemcitabine and platinum (GP) as first-line (1L) treatment for locally advanced or metastatic squamous non-small-cell lung cancer (sqNSCLC)
38. LBA57 MHC-II antigen presentation pathway as a predictive biomarker for sintilimab plus chemotherapy in first-line treatment of locally advanced or metastatic non-squamous non-small cell lung cancer (nsq-NSCLC)
39. 1176P Expression and clinical significance of PD-L1 in small cell carcinoma of the esophagus
40. 273O nextMONARCH: Final overall survival analysis of abemaciclib monotherapy or in combination with tamoxifen in patients with HR+, HER2- metastatic breast cancer
41. 218P Comparison of gene mutations between Chinese male and female breast cancer patients through next-generation sequencing
42. LBA23 - MonarcHER: A randomized phase II study of abemaciclib plus trastuzumab with or without fulvestrant versus trastuzumab plus standard-of-care chemotherapy in women with HR+, HER2+ advanced breast cancer (ABC)
43. LBA22 - Trilaciclib improves overall survival when given with gemcitabine/carboplatin (GC) in patients with metastatic triple negative breast cancer (mTNBC) in a randomized phase II trial
44. 1742PD - Trilaciclib (T) decreases myelosuppression in extensive-stage small cell lung cancer (ES-SCLC) patients receiving first-line chemotherapy plus atezolizumab
45. 495P - Participation of women in phase I oncology clinical trials
46. 331P - A phase II study of abemaciclib in patients (pts) with brain metastases (BM) secondary to non-small cell lung cancer (NSCLC) or melanoma (MEL)
47. 1666PD - Trilaciclib (T) decreases multi-lineage myelosuppression in extensive-stage small cell lung cancer (ES-SCLC) patients receiving first-line chemotherapy
48. 673P - Phase II trial of neoadjuvant therapy using apatinib plus SOX regimen in locally advanced gastric cancer: Updated results
49. 112P - Effects of concomitant genetic alterations on cancer patient overall survival
50. 75P - The landscape of NTRK fusions in Chinese patients with solid tumor
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.